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The study of Pseudomonas aeruginosa-II lectin (PA-IIL) complexes with Man derivatives as a recog-
nition factor has been neglected since its monomer is a very weak ligand. Here, the roles of Man olig-
omers and complexes in PA-IIL carbohydrate-recognition were studied by both enzyme-linked
lectinosorbent and inhibition assays. From the results obtained, it is proposed that high density
weak –OH conformation as seen in yeast mannan is also an important PA-IIL recognition factor. This
ﬁnding provides a peculiar concept of the duality of PA-IIL recognition system for LFuca1? and
related complexes and for high density Mana1? complexes present in polymannosylated target
macromolecules.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction (ELLSA) and inhibition assays [6]. Among the polysaccharides andThe wide target-cell spectrum of Pseudomonas aeruginosa
ranges from microorganisms to humans, especially patients suffer-
ing from cystic ﬁbrosis, burns and immunodeﬁciency [1,2]. Hence,
it is expected that agglutinins of this bacterium recognize a wide
range of glycoforms. Among the molecules produced from this bac-
terium for adhering to host cells, including microorganisms, two
lectins (PA-IL and PA-IIL) preferentially bind galactose and fucose,
respectively [3]. These two lectins contribute to the virulence of
this pathogenic bacterium and play important roles in promoting
serious tissue damage [1].
PA-IIL, which was discovered in 1977, is a tetrameric protein
with an average subunit molecular mass of 12.75, containing two
calcium ions in each subunit binding site [2]. In the past three dec-
ades, its structure complexes with LFuc and its derivatives has been
documented [2–5]. It was shown to be LFuc > DMan speciﬁc and to
react well with all human blood group ABH and Lewis active gly-
coproteins (gps) [5], but weakly or not at all with their precursor
gps and N-linked gps. Since Man was found to be a weaker ligand,
its role in target-recognition has been neglected. In this study, the
roles of Man oligomers and Man complexes in PA-IIL carbohydrate-
recognition were studied by both enzyme-linked lectinosorbentchemical Societies. Published by E
).N-glycans tested, mannan from Saccharomyces cerevisiae, which
has been recently shown to inhibit PA-IIL recognition [7], was
the only potent one. Collectively the present results and previous
studies lead us to propose that the extra high density of –OH
groups at carbon-2 and -4 in Mana1? as in yeast mannan (Struc-
ture II) can also be constructed into an active recognition factor.
Thus, the PA-IIL recognition system is further extended to the ﬁeld
of microbial attachment at submolecular level, establishing a novel
concept of the dual recognition system of PA-IIL through two
different carbohydrate-binding mechanisms, which might also be
applied to other lectins.
2. Materials and methods
2.1. The P. aeruginosa-II lectin (PA-IIL)
The P. aeruginosa-II lectin (PA-IIL) was puriﬁed from the bacte-
rial (ATCC 33347) extracts as previously described [3]. Biotinyla-
tion of the lectin was performed as described by Duk et al. [6].
2.2. Glycoproteins and polysaccharides
ABH and Lewis active blood group active glycoproteins (e.g.
Cyst Mcdon and Tighe) were prepared from human ovarian cystlsevier B.V. All rights reserved.
Structure I. A generalized structure of mannan isolated from yeast, Saccharomyces
cerevisiae, which consists of complex a1?6 linked DMan backbone and a1?2/
a1?3 linked side DMan chains, with Man-phosphate subbranch in the side chain of
this speciﬁc yeast species [17,18]. One of the PA-IIL dual recognition system is
proposed owing to the consistence of Mana1? and LFuc that share the same –OH
groups at carbon-2 and carbon-4 (Haworth projection, Structure II). P, phosphate.
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multi-antennary II containing N-glycans [12], were purchased
from Sigma Chemical Co. (St. Louis, MO, USA).
Desialylation of sialoglycoproteins was performed by mild acid
hydrolysis in 0.01 N HCl at 80 C for 90 min and followed by dial-
ysis against distilled H2O for 2 days to remove small fragments
[13,14].
Hog gastric mucin #4, a blood group A + H substance, was de-
rived from crude hog stomach mucin as described previously
[15]. Its acid hydrolysis with HCl at pH 2.0, 80 C, for 90 min yields
hog gastric mucin #9, while at pH 1.5, 100 C, for 2 and 5 h, hog
gastric mucins #14 and #21, respectively, are produced. Extensive
hydrolysis leads to destruction of blood group activities [16].
Mannan, which consists of complex DMan with a1?6 linkage
on backbone and a1?2/a1?3 linkages on side chains isolated
from yeast, S. cerevisiae [17,18] and poly-2,8-N-acetylneuraminic
acid capsular polysaccharide (colominic acid) from Escherichia coli
[19] were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Pneumococcus type XIV polysaccharide was prepared as described
previously [20].
Tn and sialyl Tn-containing ovine salivary glycoproteins (OSM)
and rat sublingual glycoproteins were puriﬁed according to the
procedure of Tettamanti and Pigman [13] and its modiﬁcations
[14]. Tn-glycophorin was prepared from asialo-glycophorin by
Smith degradation. Asialo glycophorin and glycophorin were pro-
vided by Lisowska and co-workers [6,21].
2.3. Sugars used for inhibition studies
Monosaccharides and oligosaccharides were purchased from
Sigma Chemical Company (St. Louis, MO, USA) and Dextra (Berk-
shire, UK).Structure II. Structures of LFuc, LGal, DAra, DMan and DGal expressed by Haworth projecti
DMan and DGal in PA-IIL recognition [5]. Shaded areas are the major combining site of P2.4. Lectinochemical assays
The assays were performed according to the procedures de-
scribed by Duk et al. [6]. The volume of each reagent applied to
the plate was 50 ll/well, and all incubations, except for coating,
were performed at room temperature. The reagents, if not indi-
cated otherwise, were diluted with TBS containing 0.05% Tween
20 (TBS-T). The TBS buffer or 0.15 M NaCl containing 0.05% Tween
20 was used for washing the plate between incubations. For inhi-
bition studies, the serially diluted inhibitor samples were mixed
with an equal volume of lectin solution containing a ﬁxed amount
of PA-IIL. The control lectin sample was diluted twofold with TBS-
T. After 30 min at room temperature, the samples were tested by
the binding assay, as described by Duk et al. [6]. The inhibitory
activity was estimated from the inhibition curve and is expressed
as the amount of inhibitor (nmol/well in Table 2 and ng in Table
3) giving 50% inhibition of the control lectin binding.
3. Results
3.1. PA-IIL interactions with diverse glycoproteins and polysaccharides
The avidities of PA-IIL to various glycoproteins and polysaccha-
rides were studied with a microtiter plate enzyme-linked lectino-
sorbent assay (ELLSA). The interaction intensities are summarized
in Table 1. Among the polyvalent glycotopes tested, PA-IIL reacted
strongly with human blood group ABH and Lewis active glycopro-
teins (#1 to #9) and with yeast mannan (#10), but not with mam-
malian N-glycans and other polysaccharides (#11 to #26),
suggesting that several LFuc related glycotopes and high density
Mana1? structures as in yeast mannan (Structure I), but not low
density Mana1? oligomers in N-glycan, play major roles in PA-
IIL recognition.
3.2. Inhibition of PA-IIL–Lewis active O-glycan interaction by mono-
and oligosaccharides (monomeric glycotopes)
In order to characterize the combining sites of PA-IIL, LFuc and
DMan related monosaccharides and oligosaccharides were used
to inhibit the interaction of PA-IIL with a human blood group H
and Lewis active O-glycan (Cyst Tighe phenol insoluble). The
amount (nmol) of these saccharides required for 50% molar inhibi-
tion of binding are listed in Table 2. Among the oligosaccharides
and mammalian glycoconjugates tested, lacto-N-fucopentaose II
(Galb1-3[Fuca1-4]GlcNAcb1-3Galb1-4Glc, the Lea active ligand)ons. Molar ratio of LFuc is about 2.4, 12, 24 and 4.4  103 more active than LGal, DAra,
A-IIL for Man.
Table 1
Binding of PA-IIL to human blood group A, B, H, Lea and Leb active, sialo- and asialo
glycoproteins (gps) by the ELLSA.a
Glycoprotein (lectin determinantsb;
blood group speciﬁcity)
1.5 (A405)
(ng)
Maximum A405
absorbance
Absorbance
reading
Binding
intensityc
Active glycoproteins and mannan
1 Cyst Mcdon (Ah) 4.5 3.0d 5+
2 Cyst N-1 Lea 20% 2 (Lea) 4.0 2.8d 5+
3 Cyst 12 (H) 10.0 2.5 5+
4 Cyst 14 phenol insoluble (Ah) 15.0 3.0d 5+
5 HOC 413 (Bh) 20.0 3.0 5+
6 Hog gastric mucin #4 (Ah, H) 29.0 2.5d 5+
7 Hog gastric mucin #9 (Ah, H) 60.0 1.7d 3+
8 Cyst Tighe phenol insoluble (H,
Leb)
75.0 2.4d 4+
9 HOC 302 (Bh) 180.0 1.6 3+
10 Mannan (high density Mana1?
complex)
190.0 2.7 5+
N-glycans and other glycoproteins/polysaccharide
11 Pneumococcus type 14 ps (II) – 0.4d ±
12 Human a1-acid gp (sialyl II) – 0.4d ±
13 Asialo human a1-acid gp (II) – 0.4d ±
14 Bovine a1-acid gp (sialyl II) – 0.0 –
15 Asialo bovine a1-acid gp (II) – 0.1 –
16 Fetuin (sialyl T, II) – 0.0d –
17 Asialo fetuin (T, II) – 0.0d –
18 Rat sublingual gp (sialyl II) – 0.1 –
19 Asialo rat sublingual gp (II) – 0.1 –
20 Hog gastric mucin #14 (A, I, II) – 0.1d –
21 Hog gastric mucin #21 (A, I, II) – 0.1d –
22 OSM (sialyl Tn, Tn) – 0.1 –
23 Asialo OSM (Tn) – 0.1 –
24 Tn-glycophorin (Tn) – 0.0 –
25 Human glycophorin (sialyl T) – 0.0 –
26 Asialo human glycophorin (T) – 0.0 –
a Two hundred nano gram of biotinylated lectin were added to various gps,
ranging from 0.016 ng to 5 lg.
b The bolded symbols in parentheses indicate the human blood group activity
and/or lectin determinants [28–30]: A (GalNAca1-3Gal); Ah (GalNAca1-3[LFuca1-
2]Gal); B (Gala1-3Gal); Bh (Gala1-3[LFuca1-2]Gal); H (LFuca1-2Gal); T (Galb1-
3GalNAc); Tn (GalNAca1-Ser/Thr); and I/II (Galb1-3/4GlcNAc).
c The results were interpreted according to the measured A405 after 2 h incuba-
tion as follows: 5+ (O.D.P 2.5), 4+ (2.5 > O.D.P 2.0), 3+ (2.0 > O.D.P 1.5), 2+
(1.5 > O.D.P 1.0), + (1.0 > O.D.P 0.5), ± (0.5 > O.D.P 0.2), and – (O.D. < 0.2).
d According to Ref. [5].
Table 2
Amount of various saccharides giving 50% molar inhibition of PA-IIL (100 ng/50 ll)
binding to a human blood group H and Lewis active glycoprotein (Cyst Tighe phenol
insoluble, 500 ng/50 ll).a
No. Inhibitor Quantity
giving 50%
inhibition
(nmol)
Relative potencyb
DMan as
1.0
LFuc as 1.0
1 0.06 100.0 4.2
2 Methyl-a-LFuc 0.13 46.2 1.9
3 LFuc 0.25 24.0 1.0
4 p-NO2-u-a- LFuc 0.3 20.0 0.8
5 LGal 0.6 10.0 0.4
6 p-NO2-u-b- LFuc 1.7 3.5 0.15
7 2.9 2.1 0.09
8 DAra 3.0 2.0 0.08
9 Mana1?3Man 4.8 1.3 0.05
10 5.2 1.2 0.05
11 Mana1?6Man 6.0 1.0 0.04
12 DMan 6.0 1.0 0.04
13 p-NO2-u-b-Man 7.0 0.9 0.04
14 Mana1?4Man 15.0 0.4 0.02
15 Mana1?2Man 15.0 0.4 0.02
16 p-NO2-u-a-Man 17.0 0.4 0.01
17 Methyl-a-Man 25.0 0.2 0.01
18 30.0 0.2 0.01
19 Methyl-b-Man 60.0 0.1 4.2  103
20 GlcNAcb1?2Man (b1-2 N-acetyl
glucosamine-mannose)
73.0 0.08 3.4  103
21 Methyl-b-LFuc 1.0  102 0.06 2.5  103
22 Gala1?6Glc (Melibiose) 8.0  102 7.5  103 3.1  104
23 DGal 1.1  103 5.5  103 2.3  104
a The inhibitory activity is expressed as the amount of inhibitor giving 50%
inhibition. Total volume is 50 ll.
b Relative potency of inhibitors compared to DMan and LFuc which were taken as
1.0.
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LFuc and DMan, respectively. Of the Man oligosaccharides tested,
only a1-3, a1-6 mannopentaose (#7), Mana1-3Man (#9), a1-3,
a1-6 mannotriose (#10) and Mana1-6Man (#11) were up to two
times as active as Man. Other Mana1-related oligosaccharides,
such as Mana1-4Man (#14), Mana1-2Man (#15) and biantennary
N-linked core pentasaccharide (#18) were slightly less active than
Man, suggesting that the major combining site for Man may be a
very small-cavity inside the pyranose of LFuc (among –OH conﬁg-
urations of carbon-2 and carbon-4, #7 to #10 in Table 2).
3.3. Inhibition of PA-IIL–Lewis active O-glycan interaction by ABH and
Lewis active glycoproteins (polyvalent LFuc glycotopes), N-glycans
(low density Man complexes) and polysaccharides (mannan and
others)
To establish the effects of polyvalent glycotopes and steric
factors in macromolecules on PA-IIL afﬁnities as described in
Sections 3.1 and 3.2, various human blood group ABH and Lewis
active glycoproteins, N- and O-glycans and polysaccharides were
used to inhibit the interaction of PA-IIL with Lewis active O-glycan
(Cyst Tighe phenol insoluble) (Table 3A). Among the glycans and
polysaccharides tested, the reactivities of blood group ABH and Le-wis active glycoproteins (#1 to #3) were only up to three times
stronger than that of LFuc (#4). High density Mana1? complexes
as in yeast mannan (#6) strongly increased reactivity reaching
up to 80% that of LFuc while other polysaccharides and N-glycans
were inactive, indicating that a high density Mana1? complex en-
hances recognition reactivity strongly. These results are in good
agreement with the interaction proﬁles described in Section 3.1
and [5].
3.4. Inhibition of PA-IIL–Mannan interaction by the diverse glycotopes
The ﬁnding that both LFuc/LFuca1? and DMan/DMana1? were
PA-IIL active ligands, DMan being 24-fold weaker than LFuc (#12 vs.
#3 in Table 2), triggered investigation of their combining site loca-
tion. For this purpose, most of the glycoforms used in Sections 3.1
and 3.3 were tested for inhibiting PA-IIL–mannan interaction. As
shown in Table 3B, monomeric LFuc was the most potent ligand
– about six times more active than mannan (#13) and human
Table 3
Amount of various glycoproteins giving 50% inhibition of PA-IIL (100 ng/50 ll) binding to Lewis active O-glycan (Cyst Tighe phenol insoluble, 500 ng/50 ll) and mannan (1.0 mg/
50 ll).a
No. Inhibitorb Quantity giving 50% inhibition (ng)c Relative potencyd
DMan as 1.0 LFuc as 1.0
A. Inhibition of PA-IIL binding to Cyst Tighe phenol insoluble
1 Cyst 12 (H active glycan) 15.0 1.5  102 2.7
2 HOC 413 (Bh active glycan) 30.0 73.3 1.3
3 Cyst 11 phenol insoluble (Ah active glycan) 30.0 73.3 1.3
4 LFuc 40.0 55.0 1.0
5 Cyst MSM 10% ppt (Ah active glycan) 50.0 44.0 0.8
6 Mannan (high density Mana1? complex) 50.0 44.0 0.8
7 DMan 2.2  103 1.0 0.02
8 Fetuin (N-glycan) >5.6  102 (15.0% inhibition) – –
9 Human a1-acid gp (N-glycan) >5.6  102 (11.4% inhibition) – –
10 Pneumococcus type 14 ps (IIb polysaccharide) >5.6  102 (8.9% inhibition) – –
11 Bovine a1-acid gp (N-glycan) >5.6  102 (5.6% inhibition) – –
B. Inhibition of PA-IIL binding to mannan
12 LFuc 13.0 92.3 1.0
13 Mannan (high density Mana1? complex) 80.0 15.0 0.2
14 Cyst 11 phenol insoluble (Ah active glycan) 85.0 14.1 0.2
15 Cyst 12 (H active glycan) 95.0 12.6 0.1
16 HOC 413 (Bh active glycan) 1.0  102 12.0 0.1
17 Hog gastric mucin #9 (Ah, H active glycan) 1.0  102 12.0 0.1
18 Cyst MSM 10% ppt (Ah active glycan) 1.4  102 8.6 0.09
19 Hog gastric mucin #4 (Ah, H active glycan) 1.4  102 8.6 0.09
20 DMan 1.2  103 1.0 0.01
21 Colominic acid (poly-sialic acid polysaccharide) >5.6  102 (11.8% inhibition) – –
22 Pneumococcus type 14 ps (IIb polysaccharide) >2.8  103 (5.0% inhibition) – –
23 Fetuin (N-glycan) >2.8  103 (0.0% inhibition) – –
24 Bovine a1-acid gp (N-glycan) >2.8  103 (0.0% inhibition) – –
a The inhibitory activity is expressed as the amount of inhibitor (ng) giving 50% inhibition. Total volume is 50 ll.
b The symbols in parentheses indicate the human blood group activity and/or lectin determinants [28–30]. Expressed in bold are: H (LFuca1-2Gal); Bh (Gala1-3[LFuca1-
2]Gal); Ah (GalNAca1-3[LFuca1-2]Gal); and IIb (Galb1-4GlcNAcb1-).
c The concentration was 5.6  102 ng for non reactive glycoproteins (Rat sublingual major-gp; Asialo bovine a1-acid gp; Asialo human a1-acid gp; Asialo fetuin) to inhibit
PA-IIL–Cyst Tighe phenol insoluble interaction and 2.8  103 ng for the non reactive ones (Rat sublingual major-gp; Asialo human a1-acid gp; Asialo fetuin) to inhibit PA-IIL–
mannan interaction.
d Relative potency of gps compared to DMan and LFuc which were taken as 1.0.
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trast to N-glycans and other polysaccharides (#21 to #24), all other
LFuc-containing glycoforms (#15 to #19) were also active inhibi-
tors. Thus, it is suggested that the combining site of PA-IIL for
Man might be located within LFuc pyranose, sharing epimers of
carbon-2 and carbon-4 of LFuc (Haworth projection, Structure II).
4. Discussion
P. aeruginosa, which can cause diseases in animals and humans,
is a common worldwide bacterium found in soil, water, skin ﬂora
and most man-made environments. Its colonization in critical body
organs [1] can be fatal. This bacterium adheres to eukaryotic host
cells and other microorganisms by several adhesive molecules,
which contribute to the virulence of this pathogenic bacterium
and play important roles in promoting serious tissue damage. P.
aeruginosa-II lectin (PA-IIL) is one of these virulence molecules
[22]. During the past three decades, the studies of PA-IIL recogni-
tion factors focused on its LFuc related ligands/glycoforms have
been well established [5,23]. Since Man was found to be a weak li-
gand, its role in recognition has not been well investigated. In this
study, the roles of Man oligomers and complexes in PA-IIL carbo-
hydrate-recognition were characterized by our established ELLSA
and inhibition assay [5]. Among the polysaccharides and N-glycans
tested, mannan from S. cerevisiae, which consists of complex DMan
with a1?6 linkage on backbone and a1?2/a1?3 linkage on side
chains (Structure I), was the most potent one. In order to identify
the locations of the combining sites of LFuc and DMan, two ap-
proaches were followed: (i) inhibition of the interaction of PA-IIL
with a Lewis active gp by many human blood group ABH/Lewis ac-tive gps (polyvalent LFuc glycotopes), mannan (a high density
Mana1? complex), N-glycans (low density Mana1? complexes),
other O-glycans (absence of mannose) and polysaccharides and
(ii) inhibition of PA-IIL–mannan interaction by the same group of
glycans and polysaccharides. It has been found that both human
blood group ABH/Lewis active glycoproteins and mannan inhibit
both interactions (Tables 2 and 3), indicating that the carbohy-
drate-recognition domain of PA-IIL for both LFuc and DMan must
be located at the same site.
As shown in Structure II and Table 2, LFuc was about 2.4, 12, 24
and 4.4  103 more active than LGal, DAra, DMan and DGal, suggest-
ing that the conﬁguration of –CH3 at carbon-5 of LFuc is the major
recognition factor and the space for carbon-6 is restricted. The con-
tribution of –OH conﬁgurations at LFuc carbons-2, -3, -4 and a1?
anomers for the binding is minor and deﬁned as a submolecular
minor site, which is proposed to be the major afﬁnity site for
Man. However, further studies are needed to conﬁrm this
assumption.
Mapping the previous and current results, it is suggested that
the interactions of PA-IIL with the tested human blood group
ABH/Lewis active glycoproteins and mannan are all glyco-related.
The combining site of PA-IIL is a small-cavity and most comple-
mentary to LFuca1? as the major site. Three submolecular active
sites involved in that recognition are: (a) conﬁguration of –CH3
at carbon-5, in which the space for carbon-6 is restricted only for
three hydrogens (#3, LFuc vs. #5, LGal, Table 2), (b) conﬁgurations
of epimeric –OH at carbon -2, -3 and -4, and (c) a1? anomeric con-
ﬁguration. The sub combining site of PA-IIL should be a groove type
to ﬁt a part of Lea active pentasaccharide (Galb1-3[Fuca1-4]Glc-
NAcb1-3Galb1-4Glc) vs. Galb1-3GlcNAcb1-3Galb1-4Glc. The Man-
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bon-2 and carbon-4 (Haworth projection) and a1? anomer of LFuc
or DMan; however, its binding intensities can be strongly enhanced
by the polyvalency of the tetrameric structure of the lectin submo-
lecular binding sites, or greatly reduced by steric hindrance. In con-
clusion, although Mana1? is a weak ligand (Table 2), an extra high
density of Mana1? complex as in yeast mannan (Structure I) can
be constructed into a new recognition factor. This ﬁnding expands
the PA-IIL recognition ﬁeld into an additional mechanism of
Mana1? complex as a recognition factor at submolecular level
and establishes a novel concept of the dual carbohydrate-recogni-
tion system for PA-IIL–glycan interactions. It is highly possible that
this dual recognition concept might also be applied to other lectin
recognition systems. Some of them are currently being investi-
gated. Recent studies have shown that PA-IIL not only reacts with
yeast mannan [7], but also with animal polymannosylated com-
pounds, such as the quail egg white (e.g. ovomucoid) gp [24] and
the bee major royal jelly (MRJP) gp [25,26], as shown by PA-IIL
hemagglutinating activity inhibition and Western blotting. Such
compounds might also serve to prevent P. aeruginosa infection-
associated pathogenicity as was recently reported by Chemani
et al. [27]. Establishment of these animal polymannosylated com-
pounds as recognition factors for our new project, requires more
detailed studies by using a series of puriﬁed glycans as described
in this study.
Acknowledgements
This work was supported by Grants from the Chang-Gung Med-
ical Research Project (CMRP Nos. 180481 and 170442), Kwei-san,
Tao-yuan, Taiwan, the National Science Council (NSC 97-2628-B-
182-002-MY3 and 97-2320-B-182-020-MY3), Taipei, Taiwan.
References
[1] Gilboa-Garber, N., Avichezer, D. and Garber, N.C. (1997) Bacterial lectins:
properties, structure, effect, function and application in: Glycosciences: Status
and Perspective (Gabius, H.J. and Gabius, S., Eds.), pp. 369–398, Chapman &
Hall, Weinheim.
[2] Mitchell, E., Houles, C., Sudakevitz, D., Wimmerova, M., Gautier, C., Pérez, S.,
Wu, A.M., Gilboa-Garber, N. and Imberty, A. (2002) Structural basis for
oligosaccharide-mediated adhesion of Pseudomonas aeruginosa in the lungs of
cystic ﬁbrosis patients. Nat. Struct. Biol. 9, 918–921.
[3] Gilboa-Garber, N. (1982) Pseudomonas aeruginosa lectins. Methods Enzymol.
83, 378–385.
[4] Sabin, C., Mitchell, E.P., Pokorná, M., Gautier, C., Utille, J.P., Wimmerová, M. and
Imberty, A. (2006) Binding of different monosaccharides by lectin PA-IIL from
Pseudomonas aeruginosa: thermodynamics data correlated with X-ray
structures. FEBS Lett. 580, 982–987.
[5] Wu, A.M., Wu, J.H., Singh, T., Liu, J.H., Tsai, M.S. and Gilboa-Garber, N. (2006)
Interactions of the fucose-speciﬁc Pseudomonas aeruginosa lectin, PA-IIL, with
mammalian glycoconjugates bearing polyvalent Lewis(a) and ABH blood
group glycotopes. Biochimie 88, 1479–1492.
[6] Duk, M., Lisowska, E., Wu, J.H. and Wu, A.M. (1994) The biotin/avidin-
mediated microtiter plate lectin assay with the use of chemically modiﬁed
glycoprotein ligand. Anal. Biochem. 221, 266–272.
[7] Zinger-Yosovich, K.D. and Gilboa-Garber, N. (2009) Blocking of Pseudomonas
aeruginosa and Ralstonia solanacearum Lectins by plant and microbial branched
polysaccharides used as food additives. J. Agric. Food Chem. 57, 6908–6913.
[8] Kabat, E.A. (1956) Blood Group Substances their Chemistry and
Immunochemistry, Academic Press, New York. pp. 135–139.[9] Wu, A.M., Kabat, E.A., Nilsson, B., Zopf, D.A., Gruezo, F.G. and Liao, J. (1984)
Immunochemical studies on blood groups. Puriﬁcation and characterization of
radioactive 3H-reduced di- to hexasaccharides produced by alkaline beta-
elimination- borohydride 3H reduction of Smith degraded blood group A
active glycoproteins. J. Biol. Chem. 259, 7178–7186.
[10] Wu, A.M. (1988) Structural concepts of the human blood group A, B, H,
Le(a)(b), I, and I active glycoprotein puriﬁed from human ovarian cyst ﬂuid.
Adv. Exp. Med. Biol. 228, 351–394.
[11] Yang, Z., Wu, A.M., Kuo, H.W., Wu, J.H. and Kannagi, R. (2009) Expression of
sialyl Lex, sialyl Lea, Lex and Ley glycotopes insecreted human ovarian cyst
glycoproteins. Biochimie 91, 423–433.
[12] Wu, A.M. and Sugii, S.J. (1988) Differential binding properties of Ga1NAc and/
or Ga1 speciﬁc lectins. Adv. Exp. Med. Biol. 228, 205–263.
[13] Tettamanti, G. and Pigman, W. (1968) Puriﬁcation and characterization of
bovine and ovine submaxillary mucins. Arch. Biochem. Biophys. 124, 41–50.
[14] Herp, A., Borelli, C. and Wu, A.M. (1988) Biochemistry and lectin binding
properties of mammalian salivary mucous glycoproteins. Adv. Exp. Med. Biol.
228, 395–435.
[15] Van Halbeek, H., Dorland, L., Vliegenthart, J.F.G., Kochetkov, N.K., Arbatsky,
N.P. and Derevitskaya, V.A. (1982) Characterization of the primary structure
and the microheterogeneity of the carbohydrate chains of porcine blood-
group H substance by 500-MHz 1H-NMR spectroscopy. Eur. J. Biochem. 127,
21–29.
[16] Wu, A.M., Lin, S.R., Chin, L.K., Chow, L.P. and Lin, J.Y. (1992) Deﬁning the
carbohydrate speciﬁcities of Abrus precatorius agglutinin as T
(Galb1?3GalNAc) > I/II (Galb1?3/4GlcNAc). J. Biol. Chem. 267, 19130–19139.
[17] Yoshida, Y., Naito, E., Mizukoshi, H., Watanabe, Y., Kimura, K., Yokoi, W., Sato,
T., Okumura, T., Ito, M. and Sawada, H.J. (2009) Side-chain structure of cell
surface polysaccharide, mannan, affects hypocholesterolemic activity of yeast.
J. Agric. Food Chem. 57, 8003–8009.
[18] Gemmill, T.R. and Trimble, R.B. (1999) Review: overview of N- and O-linked
oligosaccharide structures found in various yeast species. Biochim. Biophys.
Acta 1426, 227–237.
[19] Kwiatowski, B. and Stirm, S. (1987) Polysialic acid depolymerase. Methods
Enzymol. 138, 786–792.
[20] Lindberg, B., Lonngren, J. and Powell, D.A. (1977) Structural studies on the
speciﬁc type-14 pneumococcal polysaccharide. Carbohydrate Res. 58, 177–
186.
[21] Lisowska, E., Messeter, L., Duk, M., Czerwinski, M. and Lundblad, A. (1987) A
monoclonal anti-glycophorin A antibody recognizing the blood group M
determinant: studies on the subspeciﬁcity. Mol. Immunol. 24, 605–613.
[22] Sofer, D., Gilboa-Garber, N., Belz, A. and Garber, N.C. (1999) ‘Subinhibitory’
erythromycin represses production of Pseudomonas aeruginosa lectins,
autoinducer and virulence factors. Chemotherapy 45, 335–341.
[23] Johansson, E.M., Crusz, S.A., Kolomiets, E., Buts, L., Kadam, R.U., Cacciarini, M.,
Bartels, K.M., Diggle, S.P., Cámara, M., Williams, P., Loris, R., Nativi, C., Rosenau,
F., Jaeger, K.E., Darbre, T. and Reymond, J.L. (2008) Inhibition and dispersion of
Pseudomonas aeruginosa bioﬁlms by glycopeptide dendrimers targeting the
fucose-speciﬁc lectin LecB. Chem. Biol. 15, 1249–1257.
[24] Lerrer, B. and Gilboa-Garber, N. (2001) Interactions of Pseudomonas aeruginosa
PA-II lectin with quail egg white glycoproteins. Can. J. Microbiol. 47, 1095–
1100.
[25] Lerrer, B., Zinger-Yosovich, K.D., Avrahami, B. and Gilboa-Garber, N. (2007)
Honey and royal jelly, like human milk, abrogate lectin-dependent infection-
preceding Pseudomonas aeruginosa adhesion. ISME J. 1, 149–155.
[26] Gilboa-Garber, N. and Zinger-Yosovich, K.D. (2009) Comparison of the
antibacterial adhesion activities of honey and royal jelly in blocking lectins
of the soil-borne pathogens Pseudomonas aeruginosa, Chromobacterium
violaceum and Ralstonia solanacearum to those of milk. J. ApiProd. ApiMed.
Sci. 1, 82–89.
[27] Chemani, C., Imberty, A., de Bentzmann, S., Pierre, M., Wimmerova, M., Guery,
B.P. and Faure, K. (2009) Role of LecA and LecB lectins in Pseudomonas
aeruginosa-induced lung injury and effect of carbohydrate ligands. Infect.
Immun. 77, 2065–2075.
[28] Wu, A.M. (2001) Expression of binding properties of Gal/GalNAc reactive
lectins by mammalian glycotopes. Adv. Exp. Med. Biol. 491, 55–64.
[29] Wu, A.M. (2002) Carbohydrate structural units in glycosphingolipids as
receptors for Gal and GalNAc reactive lectins. Neurochem. Res. 27, 593–600.
[30] Wu, A.M. (2003) Carbohydrate structural units in glycoproteins and
polysaccharides as important ligands for Gal and GalNAc reactive lectins. J.
Biomed. Sci. 10, 676–688.
